Autopsy report · NCT02145078

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 2 years 9 months before it stopped.
4 participants enrolled.
Results were posted on the registry 3 years 7 months after it ended.

Vital statistics

Status: Terminated
Phase: Na
Sponsor: Barbara Ann Karmanos Cancer Institute
Sponsor type: University, hospital or other
Conditions: Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: docetaxel; pemetrexed disodium; gemcitabine hydrochloride; laboratory biomarker analysis
Participants: 4
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.